B C Baguley

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. pmc Cell cycle times of short-term cultures of brain cancers as predictors of survival
    C E Furneaux
    Department of Neurosurgery, Auckland Hospital, Auckland, New Zealand
    Br J Cancer 99:1678-83. 2008
  2. pmc Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
    Clare J Stones
    Department of Obstetrics and Gynaecology, The University of Auckland Auckland, New Zealand Auckland Cancer Society Research Centre, The University of Auckland Auckland, New Zealand
    Front Genet 4:66. 2013
  3. pmc The role of the hippo pathway in melanocytes and melanoma
    Ji Eun Kim
    Faculty of Medical and Health Sciences, Auckland Cancer Society Research Centre, The University of Auckland Auckland, New Zealand
    Front Oncol 3:123. 2013
  4. pmc Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines
    Ji Eun Kim
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    BMC Cancer 12:141. 2012
  5. ncbi request reprint Mutagenic properties of topoisomerase-targeted drugs
    B C Baguley
    Auckland Cancer Society Research Centre, University of Auckland Medical School, Private Bag 92019, Auckland, New Zealand
    Biochim Biophys Acta 1400:213-22. 1998
  6. ncbi request reprint Small-molecule cytokine inducers causing tumor necrosis
    B C Baguley
    Auckland Cancer Society Research Centre, The University of Auckland, New Zealand
    Curr Opin Investig Drugs 2:967-75. 2001
  7. ncbi request reprint The paradox of cancer cell apoptosis
    Bruce C Baguley
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    Front Biosci (Landmark Ed) 16:1759-67. 2011
  8. ncbi request reprint Short-term cultures of clinical tumor material: potential contributions to oncology research
    B C Baguley
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand
    Oncol Res 11:115-24. 1999
  9. doi request reprint ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy
    Bruce C Baguley
    Auckland Cancer Society Research Center, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Future Oncol 6:1537-43. 2010
  10. ncbi request reprint Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
    Bruce C Baguley
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1000, New Zealand
    Curr Med Chem 10:2643-9. 2003

Detail Information

Publications114 found, 100 shown here

  1. pmc Cell cycle times of short-term cultures of brain cancers as predictors of survival
    C E Furneaux
    Department of Neurosurgery, Auckland Hospital, Auckland, New Zealand
    Br J Cancer 99:1678-83. 2008
    ..Tumour cells thus appear to preserve important cytokinetic characteristics when transferred to culture...
  2. pmc Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
    Clare J Stones
    Department of Obstetrics and Gynaecology, The University of Auckland Auckland, New Zealand Auckland Cancer Society Research Centre, The University of Auckland Auckland, New Zealand
    Front Genet 4:66. 2013
    ..The high sensitivity to trametinib of some lines with wildtype BRAF status also suggests that MEK inhibitors could have a therapeutic effect against some melanomas as single agents...
  3. pmc The role of the hippo pathway in melanocytes and melanoma
    Ji Eun Kim
    Faculty of Medical and Health Sciences, Auckland Cancer Society Research Centre, The University of Auckland Auckland, New Zealand
    Front Oncol 3:123. 2013
    ....
  4. pmc Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines
    Ji Eun Kim
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    BMC Cancer 12:141. 2012
    ..We have examined the utilisation of these three signalling pathways in a number of cell lines derived from patients with metastatic malignant melanoma of known PIK3CA, PTEN, NRAS and BRAF mutational status...
  5. ncbi request reprint Mutagenic properties of topoisomerase-targeted drugs
    B C Baguley
    Auckland Cancer Society Research Centre, University of Auckland Medical School, Private Bag 92019, Auckland, New Zealand
    Biochim Biophys Acta 1400:213-22. 1998
    ..Mutagenicity of topoisomerase-directed agents has been underestimated in the past, since these drugs are not usually capable of reacting covalently with DNA and usually have low mutagenicity in microbial assays...
  6. ncbi request reprint Small-molecule cytokine inducers causing tumor necrosis
    B C Baguley
    Auckland Cancer Society Research Centre, The University of Auckland, New Zealand
    Curr Opin Investig Drugs 2:967-75. 2001
    ..Exploitation of this principle to clinical anticancer therapy represents an important challenge for the future...
  7. ncbi request reprint The paradox of cancer cell apoptosis
    Bruce C Baguley
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    Front Biosci (Landmark Ed) 16:1759-67. 2011
    ..The progeny of smaller population thus maintains the larger population. This review describes the evidence for such a model and its implications for cancer therapy...
  8. ncbi request reprint Short-term cultures of clinical tumor material: potential contributions to oncology research
    B C Baguley
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand
    Oncol Res 11:115-24. 1999
    ..We consider how application of culture methods may lead not only to the discovery of new antitumor drugs, but also to improved choice of patients' treatment...
  9. doi request reprint ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy
    Bruce C Baguley
    Auckland Cancer Society Research Center, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Future Oncol 6:1537-43. 2010
    ..Studies of changes in tumor tissue following treatment with ASA404 either alone or combined and other agents will provide new insights into the dynamics of the tumor microenvironment...
  10. ncbi request reprint Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
    Bruce C Baguley
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1000, New Zealand
    Curr Med Chem 10:2643-9. 2003
    ..Such reactions may make important contributions to the antitumor activity of these drugs...
  11. doi request reprint Multiple drug resistance mechanisms in cancer
    Bruce C Baguley
    Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
    Mol Biotechnol 46:308-16. 2010
    ..Most published work on the overcoming of MDR has concentrated on inhibition of drug transporters but the complexity of mechanisms contributing demands a broad strategy for the development of methods to overcome MDR in a clinical setting...
  12. pmc Temporal aspects of the action of ASA404 (vadimezan; DMXAA)
    Bruce C Baguley
    The University of Auckland, Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, Private Bag 92019, Auckland, New Zealand
    Expert Opin Investig Drugs 19:1413-25. 2010
    ..While their action is distinct from that of antiangiogenic agents, their clinical potential is likely to reside in improving the efficacy of combination therapy...
  13. doi request reprint Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer
    Bruce C Baguley
    Auckland Cancer Society Research Centre, The University of Auckland, New Zealand
    Clin Lung Cancer 12:81-6. 2011
    ....
  14. ncbi request reprint Novel strategies for overcoming multidrug resistance in cancer
    Bruce C Baguley
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, PB 92019, Auckland, New Zealand
    BioDrugs 16:97-103. 2002
    ..New therapeutic approaches will have to be complemented by improved diagnostic tests to evaluate the contributions of different resistance mechanisms in individual patients with cancer...
  15. doi request reprint Multidrug resistance in cancer
    Bruce C Baguley
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    Methods Mol Biol 596:1-14. 2010
    ..A number of methods of overcoming intrinsic multidrug resistance of tumours have been developed but methods for overcoming tumour resistance mediated by host cells are still at an early stage and require further research...
  16. ncbi request reprint Tumor stem cell niches: a new functional framework for the action of anticancer drugs
    Bruce C Baguley
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    Recent Pat Anticancer Drug Discov 1:121-7. 2006
    ..As well as providing opportunities for new drug discovery, this model of tumor growth also presents challenges as to how the contributions of individual drugs in a combination might be assessed in individual patients...
  17. ncbi request reprint DMXAA: an antivascular agent with multiple host responses
    Bruce C Baguley
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    Int J Radiat Oncol Biol Phys 54:1503-11. 2002
    ..To measure host responses to the antivascular agent DMXAA (5,6-dimethylxanthenone-4-acetic acid) and to compare them with those of other antivascular agents...
  18. ncbi request reprint Antivascular therapy of cancer: DMXAA
    Bruce C Baguley
    Auckland Cancer Society Research Centre, University of Auckland, New Zealand
    Lancet Oncol 4:141-8. 2003
    ..Phase I clinical trials of DMXAA have been completed and the next challenge to face is how the antivascular effect of this drug should be exploited for the treatment of human cancer...
  19. ncbi request reprint Do negative feedback oscillations drive variations in the length of the tumor cell division cycle?
    Bruce C Baguley
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Oncol Res 15:291-4. 2005
    ..The oscillatory mechanisms for p53 and NF-kappaB suggest that transitions from the cell cycle to apoptosis are also governed by probability functions...
  20. ncbi request reprint Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects
    B C Baguley
    Cancer Research Laboratory, University of Auckland School of Medicine, New Zealand
    Oncol Res 9:55-60. 1997
    ....
  21. ncbi request reprint Potential of DMXAA combination therapy for solid tumors
    Bruce C Baguley
    Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
    Expert Rev Anticancer Ther 2:593-603. 2002
    ..This review discusses the mechanisms underlying such interactions and how these might be exploited in clinical cancer treatment...
  22. ncbi request reprint In vitro modelling of human tumour behaviour in drug discovery programmes
    B C Baguley
    Auckland Cancer Society Research Centre, University of Auckland, School of Medicine, Private Bag 92019, Auckland, New Zealand
    Eur J Cancer 40:794-801. 2004
    ..The identification of cell lines that preserve potential targets is an important goal in cancer biology and research using primary cultures will help in this identification...
  23. pmc Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
    Z Cao
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand
    Br J Cancer 80:716-23. 1999
    ..Co-administration of thalidomide may represent a novel approach to improving selective intra-tumoural TNF-alpha production and anti-tumour efficacy of DMXAA...
  24. ncbi request reprint DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard
    T A Gourdie
    Cancer Research Laboratory, School of Medicine, University of Auckland, Private Bag, New Zealand
    J Med Chem 33:1177-86. 1990
    ..These results show that targeting alkylating agents to DNA by attachment to DNA-affinic units may be a useful strategy...
  25. ncbi request reprint DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain
    K K Valu
    School of Medicine, Department of Pathology, University of Auckland, New Zealand
    J Med Chem 33:3014-9. 1990
    ..Within each active series, the most active compound was the C4 homologue, suggesting some relationship between activity and extent of DNA alkylation...
  26. ncbi request reprint Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    L Zhao
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Cancer Chemother Pharmacol 47:491-7. 2001
    ..However, serum TNF concentrations were not increased, suggesting that the increased anti-tumour effects are mediated by an increased local tumour response, arising from the extended tumour DMXAA concentrations...
  27. pmc The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
    L Zhao
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Br J Cancer 87:465-70. 2002
    ....
  28. ncbi request reprint NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    S T Woon
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, Auckland University, Private Bay 92019, New Zealand
    Eur J Cancer 39:1176-83. 2003
    ..Moreover, activation of NF-kappaB in the tumour cell did not confer resistance to DMXAA-induced therapy...
  29. ncbi request reprint Neuroprotective interactions in rats between paclitaxel and cisplatin
    M J McKeage
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
    Oncol Res 11:287-93. 1999
    ..5 days) alone. Paclitaxel and cisplatin antagonized each other's neurotoxicity in Wistar rats. Combining cytotoxic agents with opposing effects on peripheral nerves has potential for minimizing neurotoxicity in patients...
  30. ncbi request reprint Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid
    S Cliffe
    Department of Pathology, University of Auckland School of Medicine, New Zealand
    Int J Radiat Oncol Biol Phys 29:373-7. 1994
    ....
  31. ncbi request reprint Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    Z Cao
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand
    Cancer Res 61:1517-21. 2001
    ..The data support the hypothesis that DMXAA, in addition to antivascular effects mediated by tumor necrosis factor-alpha, may have an antiangiogenic effect mediated largely by the induction of IP-10...
  32. pmc Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid
    L M Ching
    Cancer Research Laboratory, University of Auckland School of Medicine, New Zealand
    Br J Cancer 72:339-43. 1995
    ..The results suggest a possible new application for thalidomide and pose new questions about the action of 5,6-MeXAA and related compounds...
  33. ncbi request reprint Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA)
    D J Bridewell
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Science, The University of Auckland, New Zealand
    Anticancer Drug Des 16:317-24. 2001
    ..We hypothesize that DACA analogues act both in vitro and in vivo to simultaneously poison topo II and inhibit topo I catalytic activity, and that this combination contributes to the high antitumour activity of DACA analogues...
  34. ncbi request reprint Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents
    P Kestell
    Auckland Cancer Society Research Centre, University of Auckland Medical School, Auckland Hospital, Private Bag 92019, Auckland, New Zealand
    Clin Chim Acta 314:159-66. 2001
    ....
  35. pmc Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity
    L M Ching
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand
    Br J Cancer 78:336-43. 1998
    ..The results are compatible with the hypothesis that pharmacological reduction of serum TNF levels might benefit the anti-tumour effects of DMXAA and suggest new strategies for therapy using this agent...
  36. pmc Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid
    L M Ching
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, Private Bag 92019, Auckland, New Zealand
    Br J Cancer 86:1937-42. 2002
    ..9 mg x m(-2)). We conclude that 5,6-Dimethylxanthenone-4-acetic acid can induce vascular endothelial cell apoptosis in some murine and human tumours. The action is rapid and appears to be independent of tumour necrosis factor induction...
  37. ncbi request reprint Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans
    S F Zhou
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, New Zealand
    Xenobiotica 31:277-93. 2001
    ..The reactive properties of DMXAA-G may have important implications for the pharmacokinetics, pharmacodynamics and toxicity of DMXAA...
  38. ncbi request reprint Subcellular distribution and photocytotoxicity of aluminium phthalocyanines and haematoporphyrin derivative in cultured human meningioma cells
    G M Malham
    Department of Neurosurgery, Auckland Hospital, New Zealand
    Br J Neurosurg 10:51-7. 1996
    ..These data indicate unique features of AlPc which suggests its application as a potent, non-toxic photosensitizer in the photodynamic therapy of human meningiomas...
  39. ncbi request reprint Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes
    M J McKeage
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Science, University of Auckland School of Medicine, New Zealand
    Cancer Chemother Pharmacol 46:343-50. 2000
    ....
  40. ncbi request reprint Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs
    S A Gamage
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1000, New Zealand
    J Med Chem 44:1407-15. 2001
    ..Two compounds showed in vivo activity in murine colon 38 syngeneic and HT29 human colon tumor xenograft models using intraperitoneal dosing...
  41. pmc Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs
    C J Lash
    Department of Pathology, The University of Auckland, New Zealand
    Br J Cancer 78:439-45. 1998
    ..5 days. This study demonstrates that 5-HT and/or bioreductive drugs can improve the therapeutic activity of DMXAA in mice, and that with SN 23816 both approaches can be used together to provide considerably enhanced anti-tumour activity...
  42. ncbi request reprint Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
    M R McCrystal
    Department of Clinical Oncology, Auckland Hospital, New Zealand
    Cancer Chemother Pharmacol 44:39-44. 1999
    ..Animal data suggest that the MTD achieved with this schedule may be sub-therapeutic in humans. It is therefore important that efforts be continued to explore methods of giving higher doses of DACA...
  43. pmc Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
    L M Ching
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Br J Cancer 90:906-10. 2004
    ..These results suggest that blood flow inhibition caused by DMXAA is tumour tissue-specific and is a consequence of induction of apoptosis in tumour vascular endothelial cells...
  44. ncbi request reprint Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells
    K O Hicks
    Auckland Cancer Society Research Centre, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand
    J Pharmacol Exp Ther 297:1088-98. 2001
    ..In conclusion, this study demonstrates that it is possible to design DNA intercalators that diffuse efficiently in tumor tissue, and that there is little impediment to DACA transport over distances required for its antitumor action...
  45. ncbi request reprint The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor
    M Philpott
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, Auckland, New Zealand
    Eur J Cancer 37:1930-7. 2001
    ..Taken together, the results indicate DMXAA acts in vitro on HPBL to co-stimulate TNF production by a wide variety of agents, and suggests that IKK is the target that mediates this action...
  46. ncbi request reprint Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions
    G J Finlay
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand
    Oncol Res 11:249-54. 1999
    ..The findings are consistent with the hypothesis that low molecular weight molecules can modulate the effects of topoisomerase II poisons by directly interacting with the enzyme...
  47. ncbi request reprint Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice
    L M Ching
    Auckland Cancer Society Research Centre, University of Auckland, New Zealand
    Cancer Res 59:3304-7. 1999
    ..TNF protein was undetectable in liver and spleen tissue from TNF knockout mice, but was evident in tissue from TNF-positive mice. These results confirm that DMXAA has the novel ability of inducing tumors to synthesize TNF in situ...
  48. ncbi request reprint Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice
    Liangli Zhao
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Cancer Chemother Pharmacol 49:20-6. 2002
    ..Since oral administration has many advantages, we compared the biological activity and pharmacokinetics of DMXAA in mice following oral and intraperitoneal (i.p.) administration...
  49. pmc Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)
    M Philpott
    Cancer Research Laboratory, University of Auckland School of Medicine, New Zealand
    Br J Cancer 76:1586-91. 1997
    ..In vitro analysis of the response of human peripheral blood leucocytes to DMXAA may be a useful test in clinical trials of agents such as DMXAA...
  50. pmc Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures
    G J Finlay
    Cancer Research Laboratory, University of Auckland School of Medicine, New Zealand
    Br J Cancer 56:755-62. 1987
    ....
  51. ncbi request reprint Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    Francisco Chung
    Auckland Cancer Society Research Center, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Oncol Res 14:75-82. 2003
    ..We conclude that there is no advantage in using the nonracemizable thalidomide analogues to improve the antitumor activity of DMXAA...
  52. ncbi request reprint Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability
    Liangli Zhao
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Int J Cancer 116:322-6. 2005
    ..DMXAA might be useful clinically to potentiate the vascular permeability of other anticancer modalities such as cytotoxic drugs, antibodies, drug conjugates and gene therapy...
  53. ncbi request reprint Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling
    Liangli Zhao
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Clin Cancer Res 9:6545-50. 2003
    ..We wished to determine the relationship between administration schedule and antitumor activity...
  54. doi request reprint Analysis of radiation-induced changes to human melanoma cultures using a mathematical model
    B Basse
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    Cell Prolif 43:139-46. 2010
    ..In this study, we used the model to analyse effects of radiation on cultures of five human melanoma cell lines...
  55. ncbi request reprint Establishment of primary human meningiomas as subcutaneous xenografts in mice
    G M Malham
    Department of Neurosurgery, Auckland Hospital, Auckland, New Zealand
    Br J Neurosurg 15:328-34. 2001
    ..This study demonstrates the utility of the subcutaneous meningioma xenograft as a model for further biological and therapeutic studies...
  56. pmc Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
    M B Jameson
    Department of Clinical Oncology, Auckland Hospital, Private Bag 92024, Auckland, New Zealand
    Br J Cancer 88:1844-50. 2003
    ..The results of PK and PD studies are reported separately. DMXAA has antitumour activity at well-tolerated doses...
  57. ncbi request reprint Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial
    M B Jameson
    Department of Clinical Oncology, Auckland Hospital, Private Bag 92024, Auckland, New Zealand
    Cancer Chemother Pharmacol 59:681-7. 2007
    ..The purpose of this study was to determine the pharmacokinetics (PK) of DMXAA in cancer patients enrolled in a phase I clinical trial...
  58. ncbi request reprint DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards
    G L Gravatt
    Department of Pathology, University of Auckland School of Medicine, New Zealand
    J Med Chem 34:1552-60. 1991
    ..The modest potency may be related to their poor aqueous solubility, since the more soluble methyl quaternary salts were equally active at much lower doses...
  59. ncbi request reprint A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines
    See Tarn Woon
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Oncol Res 15:351-64. 2005
    ..The results demonstrate interspecies differences in the NF-kappaB response to XAA analogues, and may also reflect the complex nature of NF-kappaB regulation...
  60. pmc The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels
    L J Zwi
    Department of Pathology, University of Auckland School of Medicine, New Zealand
    Br J Cancer 62:231-7. 1990
    ..These results provide further evidence that FAA kills blood vessel-dependent tumour cells by interrupting the tumour blood supply...
  61. pmc Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs
    D Screnci
    Department of Pharmacology and Clinical Pharmacology, The University of Auckland, New Zealand
    Br J Cancer 82:966-72. 2000
    ..Differences in the reactivity of platinum complexes accounts for some of the variation in their neurotoxicity...
  62. ncbi request reprint Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs
    G J Finlay
    Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand
    Cancer Chemother Pharmacol 45:417-22. 2000
    ..These have been shown to reduce the free plasma concentrations of a number of anticancer drugs, particularly of those of complex organic structure, in both experimental studies and clinical trials...
  63. ncbi request reprint Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors
    Liang Chuan S Wang
    Auckland Cancer Society Research Center, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Oncol Res 16:1-14. 2006
    ....
  64. ncbi request reprint Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor
    Francisco Chung
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Cancer Chemother Pharmacol 53:377-83. 2004
    ..We wished to determine whether cyclophosphamide and DMXAA altered the t(1/2) of thalidomide. Since both thalidomide and DMXAA modulate tumour necrosis factor (TNF), we also wished to determine the role of TNF in this interaction...
  65. ncbi request reprint Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients
    Francisco Chung
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Clin Cancer Res 10:5949-56. 2004
    ..Thalidomide has a variety of biological effects that vary considerably according to the species tested. We sought to establish whether differences in pharmacokinetics could form a basis for the species-specific effects of thalidomide...
  66. pmc Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production
    L L Thomsen
    Cancer Research Laboratory, University of Auckland School of Medicine, New Zealand
    Br J Cancer 66:723-7. 1992
    ..The results provide evidence that treatment of patients with FAA and rhIL-2 induce the synthesis of nitric oxide, a physiological mediator and potential cytotoxic agent...
  67. ncbi request reprint Major changes in chromatin condensation suggest the presence of an apoptotic pathway in plant cells
    I E O'Brien
    Horticulture and Food Research Institute of New Zealand, Auckland, New Zealand
    Exp Cell Res 241:46-54. 1998
    ..The loss of reversibility of chromatin condensation observed subsequently may be a critical point in the cascade of apoptotic events, leading to further irreversible changes during apoptosis in plants...
  68. ncbi request reprint Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity
    J Y Fan
    Cancer Society Research Laboratory, Faculty of Medicine and Health Science, University of Auckland, New Zealand
    Anticancer Drug Des 12:181-203. 1997
    ..The 4-linked analogues showed slightly higher in vivo antileukemic activity than the corresponding 1'-linked analogues...
  69. ncbi request reprint 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
    Mark J McKeage
    Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand
    Clin Cancer Res 12:1776-84. 2006
    ....
  70. doi request reprint The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049
    David J A Bridewell
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019 Auckland, New Zealand
    Cancer Chemother Pharmacol 62:753-62. 2008
    ..We wished to investigate the roles of topoisomerase (topo) I, topo II and RNA transcription in the action of SN 28049...
  71. ncbi request reprint Phenazine-1-carboxamides: structure-cytotoxicity relationships for 9-substituents and changes in the H-bonding pattern of the cationic side chain
    Swarna A Gamage
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Bioorg Med Chem 14:1160-8. 2006
    ..There was generally little difference in IC(50)s between parent and P-glycoprotein expressing cell lines, suggesting that most of the compounds are not affected by the presence of this efflux pump...
  72. doi request reprint Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer
    Mark J McKeage
    Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Grafton, Auckland, New Zealand
    Cancer 116:1859-71. 2010
    ..Phase 3 clinical trials are ongoing. Selectively targeting established tumor vasculature with tumor-VDAs represents a promising and innovative approach to improving the efficacy of standard anticancer therapies...
  73. ncbi request reprint Dual topoisomerase I/II inhibitors in cancer therapy
    William A Denny
    Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 920109, New Zealand
    Curr Top Med Chem 3:339-53. 2003
    ..The basis for the high antitumor activity of some topo inhibitors is not yet understood but may depend on the complex pattern of activities that include both inhibition and poisoning of the two enzymes...
  74. ncbi request reprint Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines
    Leslie W Deady
    Chemistry Department, La Trobe University, Victoria 3086, Australia
    J Med Chem 46:1049-54. 2003
    ..Five were tested in vivo against subcutaneous colon 38 tumors in mice, and a single dose (3.9 mg/kg) proved to be curative for the 2-methyl and 2-(3,4-dimethoxyphenyl) derivatives in this refractory model...
  75. ncbi request reprint 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University ofAuckland, New Zealand
    Invest New Drugs 20:281-95. 2002
    ..Further studies are required to explore the molecular targets of DMXAA and mechanisms for the interactions with other drugs co-administered during combination treatment, which may allow for the optimisation of DMXAA-based chemotherapy...
  76. ncbi request reprint Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Pharmacol 65:109-20. 2003
    ..However, clinical studies are important to verify the conclusions drawn from in vitro data...
  77. ncbi request reprint Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid
    Shufeng Zhou
    Division of Pharmacology and Clinical Pharmacology, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Pharmacol 65:1853-65. 2003
    ..Further study is needed to examine the genotype-phenotype relationship, and the result, together with therapeutic drug monitoring may provide a useful strategy for optimizing DMXAA treatment...
  78. ncbi request reprint Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines
    See Tarn Woon
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Oncol Res 13:95-101. 2002
    ..The observed activation of NF-kappaB in some lines suggests that the effects of DMXAA on tumor cells, as well as host cells, must be considered in understanding its antitumoraction...
  79. doi request reprint Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice
    Pradeep B Lukka
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Cancer Chemother Pharmacol 65:1145-52. 2010
    ..We report here the preclinical pharmacokinetics of SN 28049...
  80. ncbi request reprint Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans
    Jun Lu
    The Auckland Cancer Society Research Center, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    J Pharmacol Exp Ther 310:571-7. 2004
    ..The very low rate of in vitro and in vivo hydroxylation in humans strongly suggests that thalidomide hydroxylation is not a requirement for clinical anticancer activity...
  81. doi request reprint Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs
    L C Steve Wang
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Invest New Drugs 27:280-4. 2009
    ..We wished to determine whether co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) could modulate the antivascular effects of DMXAA in mice...
  82. ncbi request reprint Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide
    Francisco Chung
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Cancer Chemother Pharmacol 61:497-502. 2008
    ..Thalidomide is an anti-inflammatory agent that potentiates the anti-tumour activity of DMXAA but decreases induction of TNF in plasma. We wished to determine how it potentiated the effects of DMXAA...
  83. ncbi request reprint Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites
    Liang Chuan S Wang
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Biochem Pharmacol 67:937-45. 2004
    ..The results indicate that DMXAA rather than a metabolite is responsible for cytokine induction and suggest that the microenvironment of the tumour may be responsible for the observed selective induction of cytokines in tumour tissue...
  84. pmc Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma
    K M Francis Thickpenny
    Department of Obstetrics and Gynaecology, Research Centre in Reproductive Medicine, National Women s Hospital, Auckland, Australia
    Br J Cancer 85:687-91. 2001
    ..This data supports other evidence from mutational analysis of the PTEN and beta-catenin genes that there are distinct developmental pathways responsible for the progression of different epithelial ovarian cancer histologic subtypes...
  85. pmc Nucleolar damage correlates with neurotoxicity induced by different platinum drugs
    M J McKeage
    Division of Pharmacology and Clinical Pharmacology, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand
    Br J Cancer 85:1219-25. 2001
    ..86;P< 0.024). Damage to the nucleolus of ganglionic sensory neurons is therefore linked to the neurotoxicity of platinum-based drugs, possibly through mechanisms resulting in the inhibition of rRNA synthesis...
  86. doi request reprint Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion
    Srinivas Ganta
    School of Pharmacy, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Int J Pharm 360:115-21. 2008
    ..4% vs. 49+/-7.4%, P<0.01). These results suggest that CHL-PE could be an effective parenteral carrier for chlorambucil delivery in cancer treatment...
  87. doi request reprint Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery
    Srinivas Ganta
    School of Pharmacy, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Int J Pharm 367:179-86. 2009
    ..1+/-0.1h vs 2.7+/-0.2h) compared to the ASL solution. In contrast, the ASL nanosuspension resulted in a significantly greater AUC(0-infinity) in liver, lung and kidney (all P<0.01), but not in heart...
  88. doi request reprint Activin is a potent growth suppressor of epithelial ovarian cancer cells
    Anassuya Ramachandran
    Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand
    Cancer Lett 285:157-65. 2009
    ..Thus, activin is a potent inhibitor of proliferation of some epithelial ovarian cancer cell lines and its role in the pathogenesis of this disease needs to be re-evaluated...
  89. doi request reprint Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049)
    Pradeep B Lukka
    Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    J Chromatogr B Analyt Technol Biomed Life Sci 875:368-72. 2008
    ..A bi-exponential concentration-time curve was observed with an elimination half-life of 2.3+/-0.2h (mean+/-S.E.), a volume of distribution of 34.5+/-2.2l/kg, and a plasma clearance of 12+/-0.5l/h/kg...
  90. ncbi request reprint NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA
    See Tarn Woon
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Anticancer Res 27:327-34. 2007
    ..DMXAA activates NF-kappaB in many different cell types. In this study, whether DMXAA-induced endothelial cell apoptosis was NF-kappaB dependent was determined...
  91. ncbi request reprint MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity
    Euphemia Leung
    Auckland Cancer Society Research Centre, University of Auckland Auckland, New Zealand
    Cancer Biol Ther 9:717-24. 2010
    ..The results support the conclusion that the MCF-7 cell line is heterogeneous and that the selection conditions allow the growth of pre-existing phenotypes...
  92. ncbi request reprint Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide
    Qi Ding
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand
    Cancer Chemother Pharmacol 50:186-92. 2002
    ..We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour model...
  93. ncbi request reprint Thalidomide metabolites in mice and patients with multiple myeloma
    Jun Lu
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Clin Cancer Res 9:1680-8. 2003
    ..This research examines the profile of metabolites of thalidomide that are formed in refractory multiple myeloma patients undergoing thalidomide therapy in comparison with those that are detected in healthy mice...
  94. ncbi request reprint Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
    Liangli Zhao
    Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Invest New Drugs 25:271-6. 2007
    ..Its action is incompletely understood and we wished to develop an in vitro system to study its effects...
  95. doi request reprint Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion
    Srinivas Ganta
    School of Pharmacy, The University of Auckland, Auckland, New Zealand
    J Drug Target 18:125-33. 2010
    ..This study suggests that LNE could produce remarkably improved pharmacokinetic profile and therapeutic efficacy of chlorambucil compared to non-PEG-modified nanoemulsion and solution...
  96. pmc Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity
    S M F Jamieson
    1Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    Br J Cancer 88:1942-7. 2003
    ..In conclusion, paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons after pharmacologically relevant doses in vivo and reduces oxaliplatin nucleolar damage and neurotoxicity...
  97. ncbi request reprint Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies
    Shufeng Zhou
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand
    J Chromatogr B Analyt Technol Biomed Life Sci 809:87-97. 2004
    ..DMXAA across Caco-2 monolayers was through a passive transcellular process, whereas the transport of DMXAA-G was mediated by MRP1/2...
  98. ncbi request reprint Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell lines
    Elaine S Marshall
    Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
    Oncol Res 14:297-304. 2004
    ..Responses of short-term cultures of clinical tumor material to radiation, with appropriate correction for cell cycle effects, might have the potential to provide information on radiation-induced cell death in individual patients...
  99. ncbi request reprint In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake
    Johnson J Liu
    Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland 1142, New Zealand
    J Inorg Biochem 102:303-10. 2008
    ..In conclusion, Au(I) and Ag(I) bidendate pyridyl phosphine complexes demonstrate activity against cisplatin-resistant human cancer cells and in vitro cytotoxicity that strongly depends upon their lipophilicity...
  100. ncbi request reprint Cultures of surgical material from lung cancers. A kinetic approach
    Bruce C Baguley
    Faculty of Medicine and Health Science, Auckland Cancer Society Research Centre, University of Auckland, New Zealand
    Methods Mol Med 74:527-44. 2003
  101. doi request reprint The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells
    In Young Hwang
    Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
    Cancer Lett 294:82-90. 2010
    ..Thus, p53 expression may regulate protein homeostasis by down-regulating UPS function in response to cellular stress...